此外，不少研究指出，及早发现、及时诊断乳腺癌不同临床亚型，并针对性地为个体制定精准治疗方 案，选择安全有效的治疗手段，能够显著延长乳腺癌患者生存时间并提高生活质量。殷咏梅教授补充 道，随着越来越多创新抗肿瘤药物的出现，如何为患者制定个体化精准治疗方案，以提升患者获益，成 为关注重点。"而由于乳腺癌异质性强，多学科诊疗模式应贯穿乳腺癌治疗全过程，基于循证医学的多 学科团队、综合最佳证据、专家经验和患者意愿，使患者诊治过程个性化、精准化；同时也可以优化医 疗资源使用，提高诊疗的合理性，减少偏倚，最终通过临床诊疗决策的转变，乳腺癌患者有望'活得更 长、活得更好'，实现生命长度与宽度的双重提升。" "但现实问题是，一旦发生耐药，患者后续的治疗选择就会变得非常有限。"殷咏梅教授解释说，乳腺癌 患内分泌治疗的耐药，绝大多数是和PAM通路的激活，尤其是像PIK3CA突变，AKT突变等这条信号通 路上的一些基因突变或者激活有关。"过去，内分泌治疗的一些靶向药物在没有纳入医保钱，患者每个 月的花费可能要接近3万元，这些费用对于绝大多数患者而言都是一笔难以支付的巨大开支。此次包含 靶向PAM通路创新药物在内的一批乳腺癌领域的创新 ...

Group 1: Cancer Prevention and Health Education - The 31st National Cancer Prevention and Control Publicity Week emphasizes the theme "Scientific Cancer Prevention, Healthy Living" [1] - Jiangsu Provincial People's Hospital advocates for a health-centered approach to cancer prevention, focusing on health education and improving public health literacy [1] - The hospital suggests integrating health education into its development plan, establishing dedicated health education departments, and enhancing the scientific literacy of medical staff through training [1] Group 2: Comprehensive Cancer Care - Jiangsu Provincial People's Hospital adopts a multidisciplinary treatment model, establishing specialized centers for lymphoma, gastric tumors, and thyroid cancer to manage patient care throughout the entire process [2] - The hospital has upgraded traditional treatment processes to full-cycle rehabilitation management, incorporating resources from traditional Chinese medicine, nutrition, and rehabilitation [2] - The complexity of lymphoma, with over 100 pathological subtypes, necessitates precise diagnosis and individualized treatment plans, focusing on pre-hospital assessments and post-discharge home management [2] Group 3: Research and Innovation in Cancer Treatment - There is a call for increased research into the mechanisms of lymphoma and drug resistance, as well as the exploration of clinical translation pathways [2] - Advances in basic research have led to the development of innovative therapies such as monoclonal antibodies, bispecific antibodies, and cell therapies, significantly improving clinical outcomes for lymphoma patients [2] - The goal is to translate research and clinical experiences into innovative drugs that effectively serve patients with hematological diseases and lymphomas [2]